Cancer Genetics Inc
Most Recent
TMO’s Oncomine Dx Target Test Gets CMS Coverage
On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).
TMO’s Oncomine Target Test Launch Will Boost This Business
On June 27, 2017, Thermo Fisher Scientific announced the launch of its Oncomine Dx Target Test.
